MedPath

Chlamydia and Mycoplasma in Coronary Artery Disease

Completed
Conditions
Atherosclerosis
Chlamydia Infections
Coronary Artery Disease
Mycoplasma Infections
Interventions
Other: blood sample analysis - mycoplasma and chlamydia antibodies
Registration Number
NCT00561028
Lead Sponsor
Hospital de Base
Brief Summary

To test the association between anti-Chlamydia serum titers and anti-Mycoplasma antibodies with Acute Coronary Syndromes.

Detailed Description

One hundred and twenty-six patients were divided into 4 groups: Acute Coronary Syndrome with ST-elevation, Non-ST-elevation, stable coronary artery disease, and individuals without coronary disease. Anti-Chlamydia and anti-Mycoplasma IgG antibodies were measured at baseline and after 6 months.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
138
Inclusion Criteria
  • Age >18 yrs
  • Males and females
  • Agreed to sign the informed consent
Exclusion Criteria
  • Refusal to sign the informed consent
  • Follow-up not possible
  • For the "acute" groups, time between the pain beginning and randomization >24 hours
  • Active infections
  • Use of antimicrobial agents within the last 30 days
  • End-stage diseases with life expectancy <6 months

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
1blood sample analysis - mycoplasma and chlamydia antibodiesST-elevation acute myocardial infarction.
3blood sample analysis - mycoplasma and chlamydia antibodiesknown coronary artery disease, either asymptomatic or with stable angina.
4blood sample analysis - mycoplasma and chlamydia antibodiesblood donors without known coronary artery disease.
2blood sample analysis - mycoplasma and chlamydia antibodieshigh-risk unstable angina or non-ST-elevation myocardial infarction.
Primary Outcome Measures
NameTimeMethod
Test the hypothesis that patients with acute coronary syndromes have higher levels of Chlamydia pneumonia and Mycoplasma pneumonia antibodies in comparison with patients with stable coronary artery disease or controls.6 months
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath